U.S. Study Reveals High Nutritional Deficiency Rates in Children on GLP-1 Medicines for Diabetes and Obesity
A recent U.S. study has found that approximately one in six children and teenagers (16.8%) prescribed GLP-1 receptor agonists for type 2 diabetes, severe obesity, or related metabolic conditions developed a nutritional deficiency or related complication within a year of starting treatment. The study analyzed insurance records of 2,031 young individuals aged 10 to 17 who began GLP-1 treatment between 2017 and 2022. Before starting the medication, none of these participants had a recorded nutritional deficiency. Within six months, 10.2% had been diagnosed with at least one deficiency, a figure that rose to 16.8% by the one-year mark. Vitamin D deficiency was the most common issue, affecting 12.4% of the group, followed by nutritional anemia (1.6%), iron-deficiency anemia (1.4%), and muscle loss (0.8%). The research also highlighted a significant gap in nutritional support, with only 5.8% receiving a nutrition consultation within 30 days of starting treatment, and only 23.3% by six months.